Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA1 oncogenic variants status confers therapeutic sensitivity to Bevacizumab, Olaparib in patients with High-Grade Serous Fallopian Tube Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
This statement is based on a regulatory approval from the Health Service Executive:
Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.